Inhibition of nuclear factor kappa B activation in early-stage chronic lymphocytic leukemia by omega-3 fatty acids

Cancer Invest. 2013 Jan;31(1):24-38. doi: 10.3109/07357907.2012.743553. Epub 2012 Nov 29.

Abstract

Targeting the nuclear factor kappa B (NFκB) pathway is proposed as therapy for chronic lymphocytic leukemia (CLL). We hypothesized that an omega-3 fatty acids (n-3) supplement would suppress NFκB activation in lymphocytes of Rai Stage 0-1 CLL patients. The initial dose of 2.4 g n-3/day was gradually increased to 7.2 g n-3/day. After n-3 consumption: 1) plasma n-3 increased; 2) NFκB activation was suppressed in lymphocytes; 3) in vitro sensitivity of lymphocytes to doxorubicin was increased; and 4) expression of 32 genes in lymphocytes was significantly decreased.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Blood Platelets / drug effects
  • Blood Platelets / metabolism
  • Dietary Supplements
  • Doxorubicin / therapeutic use
  • Fatty Acids, Omega-3 / administration & dosage*
  • Fatty Acids, Omega-3 / adverse effects
  • Fatty Acids, Omega-3 / blood
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / blood
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
  • Lymphocytes / drug effects
  • Lymphocytes / metabolism*
  • Male
  • Middle Aged
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • RNA, Messenger / genetics

Substances

  • Fatty Acids, Omega-3
  • NF-kappa B
  • RNA, Messenger
  • Doxorubicin